Last reviewed · How we verify
oxytocin nasal spray
oxytocin nasal spray is a Neuropeptide Small molecule drug developed by University of Electronic Science and Technology of China. It is currently FDA-approved for Autism spectrum disorder (social communication deficits), Social anxiety disorder. Also known as: Pitocin, Syntocinon® Nasal Spray, Syntocinon, Oxytocin.
Oxytocin nasal spray delivers the neuropeptide oxytocin directly to the brain via intranasal administration to modulate social bonding, trust, and emotional processing.
Oxytocin nasal spray delivers the neuropeptide oxytocin directly to the brain via intranasal administration to modulate social bonding, trust, and emotional processing. Used for Autism spectrum disorder (social communication deficits), Social anxiety disorder.
At a glance
| Generic name | oxytocin nasal spray |
|---|---|
| Also known as | Pitocin, Syntocinon® Nasal Spray, Syntocinon, Oxytocin, Syntocinon Intranasal Spray |
| Sponsor | University of Electronic Science and Technology of China |
| Drug class | Neuropeptide |
| Target | Oxytocin receptor (OXTR) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry/Neurology |
| Phase | FDA-approved |
Mechanism of action
Oxytocin is an endogenous neuropeptide that acts on oxytocin receptors in the brain to promote prosocial behaviors, emotional recognition, and social cognition. The intranasal formulation bypasses the blood-brain barrier to achieve central nervous system delivery. This mechanism has been explored for conditions involving social dysfunction and emotional processing deficits.
Approved indications
- Autism spectrum disorder (social communication deficits)
- Social anxiety disorder
Common side effects
- Nasal irritation
- Headache
- Nausea
- Transient increase in anxiety
Key clinical trials
- Evaluating the Efficacy of Intranasal Oxytocin on Chronic Pain (PHASE2, PHASE3)
- Opioid-Sparing and Pain-Reducing Properties of Syntocinon: A Dose-Effect Determination (EARLY_PHASE1)
- Oxytocin Substitution Therapy in Patients With Central Diabetes Insipidus (PHASE2)
- Oxytocin-Augmented Group Psychotherapy for Patients With Schizophrenia - an Oxytocin-dose Comparison (NA)
- OXYMIND: Oxytocin-augmented Group Psychotherapy for Patients With Schizophrenia (NA)
- A Study of the Effects of Oxytocin in Adults With Binge-eating Disorder (PHASE2)
- Intranasal Oxytocin Intervention for Caregivers to Persons With Dementia (PHASE2)
- Oxytocin and Human Defensive Responses in a Dynamic Situation (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- oxytocin nasal spray CI brief — competitive landscape report
- oxytocin nasal spray updates RSS · CI watch RSS
- University of Electronic Science and Technology of China portfolio CI
Frequently asked questions about oxytocin nasal spray
What is oxytocin nasal spray?
How does oxytocin nasal spray work?
What is oxytocin nasal spray used for?
Who makes oxytocin nasal spray?
Is oxytocin nasal spray also known as anything else?
What drug class is oxytocin nasal spray in?
What development phase is oxytocin nasal spray in?
What are the side effects of oxytocin nasal spray?
What does oxytocin nasal spray target?
Related
- Drug class: All Neuropeptide drugs
- Target: All drugs targeting Oxytocin receptor (OXTR)
- Manufacturer: University of Electronic Science and Technology of China — full pipeline
- Therapeutic area: All drugs in Psychiatry/Neurology
- Indication: Drugs for Autism spectrum disorder (social communication deficits)
- Indication: Drugs for Social anxiety disorder
- Also known as: Pitocin, Syntocinon® Nasal Spray, Syntocinon, Oxytocin, Syntocinon Intranasal Spray